Arcato Laboratories, a leader in the sustained release of anesthetics, is commercializing proprietary products to serve specialty oral healthcare practitioners, such as orthodontists and oral surgeons. Arcato’s first product, a medical device named OraWax™, targets orthodontists and their patients as the first effective treatment for oral discomfort caused by orthodontic appliances (braces). Based on intellectual property exclusively licensed to Arcato, OraWax™ will relieve the irritation and discomfort experienced by orthodontics patients. Current products are ineffective at bringing significant relief to brace patients, but medicated OraWax™ has demonstrated a significant reduction in brace patient discomfort in a controlled clinical study.
Visit our Investor Relations page!
OraWax™, Arcato’s lead product, is a patented time-release formulation combining wax, benzocaine, and special polymers. Patients who apply this medicated wax to their orthodontic brackets experience relief from discomfort by reduction of friction between the bracket and the mouth, and by the sustained release of benzocaine from the wax matrix. In a clinical trial in patients who were being fitted with braces for the first time, OraWax™ was compared to regular (unmedicated) orthodontic wax. A highly significant difference in the level of pain was observed between patients using OraWax™ and patients using the regular wax. In fact, patients using OraWax™ experienced a four-fold decrease in reported pain, and relief was seen as early as one hour after administration. The results of this study were published in the American Journal of Orthodontics and Dentofacial Orthopedics.
Arcato Laboratories Selected to Participate in CED Tech Venture Conference
DURHAM, N.C., August 8, 2016 – Arcato Laboratories, developer of OraWaxTM, a revolutionary new treatment for the discomfort caused by orthodontic braces, has been selected to participate at the CED Tech Venture Conference, being held September 13-14, 2016 at the Convention Center in Raleigh, North Carolina. Arcato will have a booth featuring its groundbreaking technology in the Demo Room of the conference.
“The technology platform of Arcato Laboratories is based upon a patented method of delivering a local anesthetic to oral mucosal membranes over a sustained period of time,” said Meldrum. “The Arcato technology platform has many applications for other types of pain relief, but the OraWax™ product alone has an estimated market of about $400 million per year,” he added.
As the premier event for technology entrepreneurs and investors in the Southeast, CED Tech Venture Conference attracts some of the most innovative minds from across the nation to Raleigh, North Carolina, recently ranked #5 tech hotspot.
Arcato is currently raising $1 million in a Series B round of financing, to complete 510(k) FDA regulatory clearance for OraWax™, and launch the product in the United States.
About Arcato Laboratories
Arcato Laboratories, a leader in the sustained release of anesthetics, is commercializing proprietary products to serve specialty oral healthcare practitioners, such as orthodontists and oral surgeons. Arcato’s first product, a medical device named OraWax™, targets orthodontists and their patients as the first effective treatment for oral discomfort caused by orthodontic appliances (braces). For more information on investing, please visit our Investor Relations Page.
Christopher S. Meldrum
President & CEO
Mr. Meldrum serves as President & CEO of Arcato. Mr. Meldrum is a serial entrepreneur, having launched multiple successful start-up companies in the biotechnology and medical devices sectors from university-based technology. In addition to his work with Arcato, Mr. Meldrum serves as a Managing Director of Golden Pine Ventures, LLC. Read More …
Michael Jay, Ph.D.
Chief Scientific Officer
Dr. Jay is a Founder of Arcato and serves as Chief Scientific Officer. Dr. Jay is the Fred Eshelman Chair and distinguished professor of molecular pharmaceutics at the University of North Carolina at Chapel Hill, and is an expert on drug delivery and formulations. Dr. Jay joined the UNC Eshelman School of Pharmacy in 2008 after a 27 year career at the University of Kentucky College of Pharmacy. Read More …
Robert M. Jordan
Chief Commercial Officer
Mr. Jordan serves as Chief Commercial Officer for Arcato. Over his career, Mr. Jordan has run a variety of companies, obtaining a strong knowledge of manufacturing, services and publishing. He has a history as an innovative leader developing numerous high performance teams. In addition, Mr. Jordan has orchestrated the successful turnaround of eight companies, improving shareholder value while retaining several hundred jobs in his 25 years of professional endeavors. Read More …
Advisor, Oral Health Product Marketing
Mr. Scott serves as Oral Health Product Marketing Advisor for Arcato. Mr. Scott is currently a Partner with HealthQuest Capital, a Sofinnova fund which he helped launch in 2013. Randy’s industry successes include starting NovaMin Technology, Inc., and leading it through financing, growth and eventual acquisition by GlaxoSmithKline (at a 10x return on capital); Read More …
G. Thomas Kleumper, DMD, MS
Advisor, Orthodontic Affairs
Dr. Kleumper services as orthodontic affairs advisor for Arcato. Dr. Kleumper works as Chief and Program Director of the Division of Orthodontics at the University of Kentucky, and is co-inventor of the patented technology behind the OraWax™ product. Dr. Kleumper has received a number of awards and accolades for his work in orthodontics research. Dr. Kleumper’s clinical practice inspired him to seek a solution for his patients’ oral brace discomfort, leading eventually to a partnership with Dr. Jay and the patented OraWax™ technology.
- Connect with us via social media
- Get engaged via Investor Relations